Longevity & AgingNew Clinical Trial Standards Could Accelerate Dementia Behavioral Treatment Development
Researchers have developed comprehensive guidelines for conducting clinical trials targeting neuropsychiatric symptoms in dementia, including agitation, psychosis, and apathy. Using CONSORT reporting standards, they outline best practices for trial design, biomarker use, and outcome measurement. The guidelines emphasize innovative approaches like Bayesian adaptive designs and sequential parallel comparisons to overcome high placebo response rates that have hindered previous trials. With only two approved treatments for behavioral symptoms in dementia worldwide, these standardized methods could accelerate development of desperately needed therapies for the 80% of Alzheimer's patients who experience these disabling symptoms.
